BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27824639)

  • 1. Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance.
    Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Joo KR; Lee JI
    J Clin Gastroenterol; 2017 Oct; 51(9):825-830. PubMed ID: 27824639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
    Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
    Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms.
    Chiu HM; Ching JY; Wu KC; Rerknimitr R; Li J; Wu DC; Goh KL; Matsuda T; Kim HS; Leong R; Yeoh KG; Chong VH; Sollano JD; Ahmed F; Menon J; Sung JJ;
    Gastroenterology; 2016 Mar; 150(3):617-625.e3. PubMed ID: 26627608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
    Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening.
    Stegeman I; van Doorn SC; Mundt MW; Mallant-Hent RC; Bongers E; Elferink MA; Fockens P; Stroobants AK; Bossuyt PM; Dekker E
    Cancer Epidemiol; 2015 Jun; 39(3):388-93. PubMed ID: 25910865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght-Trinity College colorectal cancer screening programme with the faecal immunological test.
    McNamara D; Leen R; Seng-Lee C; Shearer N; Crotty P; Neary P; Walsh P; Boran G; O'Morain C
    Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1415-21. PubMed ID: 25244415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Participation rate and detection of colorectal neoplasms based on multi-round fecal immunochemical testing for colorectal cancer screening in the Chinese population].
    Li N; Zhou YY; Lu M; Zhang YH; Lu B; Luo CY; Luo JH; Cai J; Chen HD; Dai M
    Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):1041-1050. PubMed ID: 38110312
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.
    Jensen CD; Corley DA; Quinn VP; Doubeni CA; Zauber AG; Lee JK; Zhao WK; Marks AR; Schottinger JE; Ghai NR; Lee AT; Contreras R; Klabunde CN; Quesenberry CP; Levin TR; Mysliwiec PA
    Ann Intern Med; 2016 Apr; 164(7):456-63. PubMed ID: 26811150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rates on the acceptance of colonoscopy, fecal immunochemical test and a novel risk-adapted screening approach in the screening programs of colorectal cancer as well as related associated factors].
    Chen HD; Lu M; Liu CC; Zhang YH; Zou SM; Shi JF; Ren JS; Li N; Dai M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Oct; 41(10):1655-1661. PubMed ID: 33297622
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia.
    Grobbee EJ; Schreuders EH; Hansen BE; Bruno MJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
    Gastroenterology; 2017 Nov; 153(5):1251-1259.e2. PubMed ID: 28760383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenoma Detection Rate in Asymptomatic Patients with Positive Fecal Immunochemical Tests.
    Kligman E; Li W; Eckert GJ; Kahi C
    Dig Dis Sci; 2018 May; 63(5):1167-1172. PubMed ID: 29468377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participation in a population-based screening for colorectal cancer using the faecal immunochemical test decreases mortality in 5 years.
    Idigoras Rubio I; Arana-Arri E; Portillo Villares I; Bilbao Iturribarrria I; Martínez-Indart L; Imaz-Ayo N; de la Cruz M; de Castro V; López de Munain A; Torrejón Perez I; Gutiérrez-Ibarluzea I
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):197-204. PubMed ID: 30543575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
    Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
    Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferences and acceptance of colorectal cancer screening in Thailand.
    Saengow U; Chongsuwiwatvong V; Geater A; Birch S
    Asian Pac J Cancer Prev; 2015; 16(6):2269-76. PubMed ID: 25824749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.